SMARCB1 and lung carcinoma: Bladder tumour cells with the presence of reduced SNF5 expression show increased sensitivity to gefitinib, FDA approved EGFR‐targeted drug for lung cancer treatment [58], EGFR‐targeted drugs may be an effective approach for treating SNF5‐deficient bladder cancer associated with drug resistance.